Trials / Terminated
TerminatedNCT00740181
Decitabine, Cytarabine, GCSF for Refractory AML/MDS
A Phase II Study With Decitabine, Low Dose Cytarabine and G-CSF in High-risk Myelodysplastic Syndromes, Refractory Acute Myeloid Leukemia or Acute Myeloid Leukemia in Patients With Significant Co-morbidities.
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Brown University · Academic / Other
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
This study will determine the activity of decitabine, low dose cytarabine (ARA-C) and G-CSF for patients with myelodysplasia and leukemia.
Detailed description
The primary objective of this study is to determine the feasibility and toxicity of decitabine, ARA-C and G-CSF for patients with myelodysplasia, refractory acute leukemia and poor performance status acute leukemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | chemotherapy |
Timeline
- Start date
- 2008-08-01
- Primary completion
- 2010-02-01
- Completion
- 2010-04-01
- First posted
- 2008-08-22
- Last updated
- 2022-01-14
- Results posted
- 2013-07-02
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00740181. Inclusion in this directory is not an endorsement.